Galecto, Inc.

Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.

GLTO | US

Overview

Corporate Details

ISIN(s):: US36322Q1076
LEI:
Country:: United States of America
Address:: 75 STATE STREET, 2109 BOSTON
Website:: https://galecto.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galecto, Inc. is a clinical-stage biotechnology company that pioneers novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its extensive research in galectin biology to develop galectin-3 modulators, targeting key pathways in fibrosis and cancer progression. Galecto has expanded its oncology pipeline to include dual ENL-YEATS and FLT3 inhibitors for treating specific genetic subsets of acute myeloid leukemia (AML). Its research focuses on critical disease drivers in various cancers, including melanoma and carcinomas, as well as severe fibrotic liver conditions. The company's mission is to develop highly efficacious and well-tolerated treatments to extend and improve the quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galecto, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galecto, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Galecto, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL
HYUNDAI BIOLAND Co.,Ltd. Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.	South Korea	052260